SELLAS Life Sciences Group, Inc. (SLS) Latest Company News

Nov 4, 2026, 14:00 UTC
SELLAS Life Sciences announced that it will present completed Phase 2 data on SLS009 combined with azacitidine and venetoclax in relapsed or refractory AML at the ASH Annual Meeting.
Source:
- globenewswire.com
Oct 29, 2026, 12:28 UTC
3D Medicines, Inc. said the phase III REGAL trial of 3D189 (Galinpepimut-S) for acute myeloid leukemia reached its prespecified 80-death event threshold, triggering final analysis.
Source:
- finance.sina.cn
Oct 29, 2026, 12:28 UTC
SELLAS will lock the database, unblind the study data and conduct the primary-endpoint analysis, then publish preliminary topline results this quarter.
Source:
- finance.sina.cn
Sep 25, 2026, 17:00 UTC
SELLAS Life Sciences presented preclinical data showing SLS009 (tambiciclib) activity in patient-derived organoid models of pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic Cancer in San Diego on September 25, 2026.
Source:
- globenewswire.com
Aug 27, 2026, 17:13 UTC
SELLAS Life Sciences Group Inc. stock surged on Thursday, with a year-to-date gain of about 300%.
Source:
- benzinga.com
Aug 24, 2026, 14:06 UTC
Sellas Life Sciences shares fell 7.66% to $14.28 on August 24, 2026, after a German media report speculated that the REGAL Phase 3 trial may have reached the 80th event needed for final analysis, but the company has not officially confirmed this, leaving retail investors skeptical.
Source:
- s.kabutan.jp
Aug 18, 2026, 04:35 UTC
3D Medicines announced that the arbitration award in its favor against SELLAS Life Sciences Group has been fully executed, with SELLAS ordered to pay approximately 7.983 million yuan in costs, which has been received in full.
Source:
- aastocks.com
Aug 17, 2026, 05:17 UTC
Goldman Sachs increased its stake in Capricor Therapeutics by 73% to 1.58 million shares valued at $38 million, and disclosed holdings in Sellas Life Sciences and ImmunityBio totaling nearly $75 million.
Source:
- stocktwits.com
Aug 11, 2026, 20:05 UTC
SELLAS Life Sciences Group reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Source:
- globenewswire.com
Jun 26, 2026, 16:30 UTC
Sellas Life Sciences board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
Source:
- invezz.com

SLS

SELLAS Life Sciences announced that it will present completed Phase 2 data on SLS009 combined with azacitidine and venetoclax in relapsed or refractory AML at the ASH Annual Meeting.

3D Medicines, Inc. said the phase III REGAL trial of 3D189 (Galinpepimut-S) for acute myeloid leukemia reached its prespecified 80-death event threshold, triggering final analysis.

SELLAS will lock the database, unblind the study data and conduct the primary-endpoint analysis, then publish preliminary topline results this quarter.

SELLAS Life Sciences presented preclinical data showing SLS009 (tambiciclib) activity in patient-derived organoid models of pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic Cancer in San Diego on September 25, 2026.

SELLAS Life Sciences Group Inc. stock surged on Thursday, with a year-to-date gain of about 300%.

Sellas Life Sciences shares fell 7.66% to $14.28 on August 24, 2026, after a German media report speculated that the REGAL Phase 3 trial may have reached the 80th event needed for final analysis, but the company has not officially confirmed this, leaving retail investors skeptical.

3D Medicines announced that the arbitration award in its favor against SELLAS Life Sciences Group has been fully executed, with SELLAS ordered to pay approximately 7.983 million yuan in costs, which has been received in full.

Goldman Sachs increased its stake in Capricor Therapeutics by 73% to 1.58 million shares valued at $38 million, and disclosed holdings in Sellas Life Sciences and ImmunityBio totaling nearly $75 million.

SELLAS Life Sciences Group reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Sellas Life Sciences board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.